In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.
Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organisations into close, purposeful proximity, providing a structural foundation for c...
In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.
Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organisations into close, purposeful proximity, providing a structural foundation for collaboration at scale.
In this special live recording of the pharmaphorum podcast, developed in association with Bruntwood SciTech, Bruntwood SciTech’s CSO Dr Kath Mackay, Manchester University NHS Foundation Trust T’s Dr Katherine Boylan, and Dr Gillian Dalgliesh from QIAGEN join Deep Dive editor Eloise McLennan onstage at the opening of Citylabs 4.0 to discuss innovation in life sciences and the role of Greater Manchester in accelerating research, industry collaboration, and real-world evidence generation.
Join us as we examine how this deliberate integration of healthcare stakeholders in Manchester is establishing new standards for collaboration and advancing patient outcomes through structured knowledge exchange.
About the interviewees
Dr Kath Mackay
Kath Mackay is Chief Scientific Officer of Bruntwood SciTech - a JV between leading property developer Bruntwood, Legal & General, and Greater Manchester Pension Fund - the UK’s leading creator and developer of innovation districts driving growth of the UK science and technology sector. She has a keen interest in growing businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a science and tech organisation.
Dr Mackay joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing businesses working in the biomedical, health, agriculture, and food sectors, creating and delivering a £800m portfolio of infrastructure, Catapults, grant and loan investments. She is also non-executive director of the Northern Health Science Alliance, the North of England’s health partnership, and an elected fellow of the Royal Society of Biology.
Dr Katherine Boylan
Katherine is Director of Innovation at Manchester University NHS Foundation Trust (MFT), a position she has held since April 2020. This role involves overseeing innovation activities within MFT, as part of the wider Research and Innovation function. Innovation at MFT supports the whole pipeline from ideation, through to evidence generation, and ultimate implementation.
She has been a member of the NICE Medical Technologies Advisory Committee since September 2020.
Prior to this position, Dr Boylan worked in the University of Manchester for a number of years, most recently as Operations Director for the MRC funded Molecular Pathology Node, and the Trust-funded Diagnostics and Technology Accelerator.
Dr Gillian L Dalgliesh, PhD
Global Technical lead, Precision Diagnostics
Gillian Dalgliesh has worked for QIAGEN for nine years and is based at their Manchester site, which is the global centre of excellence for molecular diagnostic development. QIAGEN partner with many drug companies to develop companion diagnostic (CDx) tests that enable clinical trials and subsequently launches of novel precision medicines. In recent years they have seen a real move beyond oncology into other disease areas such as immune, neurological and metabolic disorders. Dr Dalgliesh’s role as global technical lead allows her to leverage her oncology precision medicine experience across the portfolio to bring precision diagnostic products to more patients. She has built her experience in precision medicine/oncology through not only her QIAGEN role but also through seven years working in precision medicine in AstraZeneca and prior to that working as part of the cancer genome project at the Sanger institute.
Dr Dalgliesh is also an honorary senior lecturer at University of Manchester where she coordinates and delivers lectures for a QIAGEN sponsored BSc final year elective module ‘The Role of Diagnostics in Medicine’. This is part of a wider outreach role with the University and our NHS hospital. Through these roles she is keen to impact the local UK science community.
About Bruntwood SciTech
Bruntwood SciTech is the UK’s largest dedicated property platform serving the growth of the nation’s knowledge economy to become a global science and technology superpower. It is also the leading developer of city-wide innovation ecosystems and specialist environments, helping companies - particularly those in the science and technology sectors - to form, scale and grow
A joint venture between Bruntwood, Legal & General and the Greater Manchester Pension Fund (GMPF), Bruntwood SciTech provides high quality office and laboratory space and tailored business support, offering unrivalled access to finance, talent and markets, an extensive clinical, academic and public partner network and a sector-specialist community of more than 1100 companies.
Bruntwood SciTech is experienced in creating and developing strategic partnerships with UK regional cities, universities and NHS Trusts to drive economic growth. Its unique structure and funding vehicle more easily deploys long-term patient capital in innovation infrastructure, ensuring local economic benefit and growth.
Valued at £1.5bn, Bruntwood SciTech has a portfolio of 5.2m sq ft across 11 campus locations and 31 city centre innovation hubs in Manchester, Cheshire, Birmingham, Leeds, Liverpool, Cambridge and London. It has plans to create a £5bn portfolio by 2033 and has a 2.3m sq ft secured development pipeline.
Its campus locations include Alderley Park in Cheshire; West Village in Leeds; Innovation Birmingham; Birmingham Health Innovation Campus in partnership with the University of Birmingham; Melbourn Science Park in Cambridgeshire; Liverpool Science Park as a shareholder in Sciontec Liverpool; White City Deep Tech Campus in partnership with Imperial College London; and a cluster in the heart of Manchester’s Oxford Road Corridor knowledge quarter - Manchester Science Park, Citylabs in partnership with Manchester University NHS Foundation Trust (MFT), Circle Square - a joint venture with Vita Group; and the £1.7bn JV partnership with The University of Manchester - Sister, formerly known as IDManchester.
Its city centre innovation hubs include Bloc, Bond, 111 Piccadilly, Pall Mall and Manchester One in Manchester; Platform in Leeds; Cornerblock and Centre City in Birmingham; and The Plaza in Liverpool.
Website / Twitter / LinkedIn / Instagram
